Parkinson's drug shows promise in cutting eye injections for wet AMD
NCT ID NCT03023059
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This study tested a drug normally used for Parkinson's disease (carbidopa-levodopa) in 35 people with wet age-related macular degeneration (AMD). The goal was to see if it could improve vision and reduce the need for standard eye injections. Participants took the oral drug alongside their usual treatment, and researchers measured changes in eyesight and retinal thickness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Robert W Snyder, MD, PhD, PC
Tucson, Arizona, 85712, United States
Conditions
Explore the condition pages connected to this study.